The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Open accessAbstract
Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is an increasingly recognized treatment complication in patients treated with radiotherapy or chemotherapy for previous hematologic malignancies or solid tumors. Distinct clinical entities have been described according to the primary treatment, corresponding to defined genetic lesions. Chromosome 7 and/or 5 losses or deletions are typical of alkylating agent-induced AML, while development of t-AML with balanced translocations involving chromosome bands 11q23 and 21q22 has been related to previous therapy with drugs targeting DNA-topoisomerase II. In addition, antimetabolites, and in particular the immunosuppressant azathioprine, have been shown to induce defective DNA-mismatch repair. This could promote survival of misrepaired cells giving rise to the leukemic clone. Individual predisposing factors, including polymorphisms in detoxification and DNA repair enzymes have been identified. Their combination may significantly increase the risk of t-MDS/AML. Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy. Patients with Hodgkin's and non-Hodgkin's lymphoma are at highest risk when total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation therapy. The addition of granulocyte-colony-stimulating factor and radiotherapy plays a significant role in t-AML following treatment of children with acute lymphoblastic leukemia. In non-hematologic malignancies, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of both lymphoid as well as myeloid leukemia. In all cases the risk of t-MDS/AML drops sharply by 10 years after treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Secondary cancers are frequently acute myeloid leukaemias 155 , which may be caused by previous exposure to DNA-damaging alkylators, often arising after a median of around 7 years after initial treatment 158 .”
From Osteosarcoma (2022) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edwards, B. K., Brown, M. L., Wingo, P. A., Howe, H. L., Ward, E., Ries, L. A. G., Schrag, D., Jamison, P. M., Jemal, A., Wu, X. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji289 · Cited by 955
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G. A. N., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 921
Smith, S. M., Beau, M. M. L., Huo, D., Karrison, T. G., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 681
Hematotoxicity in Workers Exposed to Low Levels of Benzene
Qing Lan, B., Zhang, L., Li, G., Vermeulen, R. C. H., Weinberg, R. S., Dosemeci, M., Rappaport, S. M., Shen, M., Alter, B. P., Wu, Y., et al. (2004) · Science · doi:10.1126/science.1102443 · Cited by 651
Environment and Cancer: Who Are Susceptible?
Perera, F. P. (1997) · Science · doi:10.1126/science.278.5340.1068 · Cited by 638
Finazzi, G. (2004) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 433
Pharmacogenomics, Regulation and Signaling Pathways of Phase I and II Drug Metabolizing Enzymes
Rushmore, T. H., & Kong, A.-N. T. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337171 · Cited by 425
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 416
Sterkers, Y., Preudhomme, C., Laï, J., Demory, J., Caulier, M. T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 369
Homologous repair of DNA damage and tumorigenesis:the BRCA connection
Jasin, M. (2002) · Oncogene · doi:10.1038/sj.onc.1206176 · Cited by 363
Research works printed but not linked: 4
- Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
- Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophillotoxins for acute lymphocytic leukemia. N Engl J Med 2001;325,1682-7.
- Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the inci- dence of the myelodisplasic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatement for myelomatosis. Br J Cancer 1987;55:523-9.
- Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagre- lide in high-risk essential thrombocy- themia. N Engl J Med 2005;353: 33-45.
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V. R., Bixby, D. L., Blum, W. G., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 648
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. L., Coutre, S. E., Lima, M. J. G. D., Fathi, A. T., Fiorella, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0028 · Cited by 423
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Wood, M. E., Vogel, V. G., Ng, A. K., Foxhall, L. E., Goodwin, P. J., & Travis, L. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8681 · Cited by 325
O'Donnell, M. R., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Attar, E. C., Borate, U., Coutre, S. E., Damon, L. E., Goorha, S., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0103 · Cited by 327
Lustberg, M. B., Kuderer, N. M., Desai, A. P., Bergerot, C. D., & Lyman, G. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00776-9 · Cited by 344
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Demark‐Wahnefried, W., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 265
Cancer Incidence in Systemic Sclerosis: Meta‐Analysis of Population‐Based Cohort Studies
Ōnishi, A., Sugiyama, D., Kumagai, S., & Morinobu, A. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37969 · Cited by 188
Lyman, G. H., Dale, D. C., Wolff, D. A., Culakova, E., Poniewierski, M. S., Kuderer, N. M., & Crawford, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8723 · Cited by 182
Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L
Chen, D.-H., Below, J. E., Shimamura, A., Keel, S., Matsushita, M. M., Wolff, J., Sul, Y., Bonkowski, E. S., Castellà, M., Taniguchi, T., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.04.009 · Cited by 178
Hepatosplenic T cell lymphoma in inflammatory bowel disease: Table 1
Shale, M., Kanfer, E., Panaccione, R., & Ghosh, S. K. (2008) · Gut · doi:10.1136/gut.2008.163279 · Cited by 158
Fishbein, L. M., Rivero, J. D., Else, T., Howe, J. R., Asa, S. L., Cohen, D. L., Dahia, P. L. M., Fraker, D. L., Goodman, K. A., Hope, T. A., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001792 · Cited by 161
Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study
Olesen, A. B., Sværke, C., Farkas, D. K., & Sørensen, H. T. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09861.x · Cited by 149
Nardo, P. D., Lisanti, C., Garutti, M., Buriolla, S., Alberti, M., Mazzeo, R., & Puglisi, F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2151584 · Cited by 163
Eichenauer, D. A., Thielen, I., Haverkamp, H., Franklin, J. G., Behringer, K., Halbsguth, T. V., Klimm, B. C., Diehl, V., Sasse, S., Rothe, A., et al. (2014) · Blood · doi:10.1182/blood-2013-07-512657 · Cited by 139
Ophthalmic manifestations of leukemia
Talcott, K. E., Garg, R. J., & Garg, S. J. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000309 · Cited by 130
Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues
Hijiya, N., Ness, K. K., Ribeiro, R. C., & Hudson, M. M. (2008) · Cancer · doi:10.1002/cncr.23988 · Cited by 118
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017008227 · Cited by 112
Incidence and susceptibility to therapy-related myeloid neoplasms
Leone, G. G. M., Fianchi, L., Pagano, L., & Voso, M. T. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.12.013 · Cited by 104
Self-citationCytogenetic and genetic pathways in therapy-related acute myeloid leukemia
Qian, Z., Joslin, J. M., Tennant, T. R., Reshmi, S. C., Young, D. J., Stoddart, A., Larson, R. A., & Beau, M. M. L. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.11.025 · Cited by 103
Steensma, D. P. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0140-3 · Cited by 99
Elter, T., Gercheva, L., Pylylpenko, H., Robak, T., Jaksic, B. S., Rekhtman, G. B., Kyrcz‐Krzemień, S., Vatutin, M. T., Wu, J., Sirard, C. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70242-x · Cited by 92
Diagnosis and treatment of therapy-related acute myeloid leukemia
Strickland, S. A., & Vey, N. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103607 · Cited by 102
A review of the potential association between childhood leukemia and benzene
Pyatt, D. W., & Hays, S. M. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.01.002 · Cited by 76
Grosjean-Raillard, J., Tailler, M., Adès, L., Perfettini, J., Fabre, C., Braun, T., de Botton, S., Fenaux, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.457 · Cited by 74
Acute myeloid leukemia developing in patients with autoimmune diseases
Ramadan, S. M., Fouad, T. M., Summa, V., Hasan, S. K., & Lo‐Coco, F. (2011) · Haematologica · doi:10.3324/haematol.2011.056283 · Cited by 74
Hasskarl, J., Ihorst, G., Pasquale, D. D., Schröttner, P., Zerweck, A., Wäsch, R., & Engelhardt, M. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.529207 · Cited by 71
Myelodysplastic syndromes: biology and treatment
Jädersten, M., & Hellström‐Lindberg, E. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02052.x · Cited by 65
Morton, L. M., Saber, W., Baker, K. S., Barrett, A. J., Bhatia, S., Engels, E. A., Gadalla, S. M., Kleiner, D. E., Pavletic, S. Z., & Burns, L. J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.005 · Cited by 68
Shivakumar, R., Tan, W., Wilding, G. E., Wang, E. S., & Wetzler, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn182 · Cited by 63
Blood disorders typically associated with renal transplantation
Yu, Y., Yu, B., & Chen, Y. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00018 · Cited by 61
Therapy-related myeloid neoplasms
Leone, G. G. M., Fianchi, L., & Voso, M. T. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834bcc2a · Cited by 59
Self-citationThe risk of cancer development in systemic sclerosis: A meta-analysis
Zhang, J., Wan, Y.-N., Peng, W., Yan, J., Li, B., Mei, B., Chen, B., Yao, H. C., Yang, G., Tao, J., et al. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.04.014 · Cited by 56
Systemic Sclerosis Association with Malignancy
Lepri, G., Catalano, M., Bellando-Randone, S., Pillozzi, S., Giommoni, E., Giorgione, R., Botteri, C., Matucci‐Cerinic, M., Antonuzzo, L., & Guiducci, S. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08930-4 · Cited by 53
Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes
Foran, J. M., & Shammo, J. M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.015 · Cited by 52
Mahmoodi, M., Soleymanjahi, S., Zendehdel, K., Mozdarani, H., Azimi, C., Farzanfar, F., Safari, Z., Mohagheghi, M. A., Khaleghian, M., Divsalar, K., et al. (2016) · Drug and Chemical Toxicology · doi:10.1080/01480545.2016.1209678 · Cited by 49
Myeloid disorders after autoimmune disease
Boddu, P. C., & Zeidan, A. M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.002 · Cited by 48
Saenko, Y., Cieślar‐Pobuda, A., Skonieczna, M., & Rzeszowska‐Wolny, J. (2013) · Radiation Research · doi:10.1667/rr3247.1 · Cited by 46
TNF-α Regulates the Effects of Irradiation in the Mouse Bone Marrow Microenvironment
Cachaço, A. S., Carvalho, T., SANTOS, A. C. D. S., Igreja, C., Fragoso, R., Osório, C., Ferreira, M. M., Serpa, J., Correia, S., Pinto‐do‐Ó, P., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008980 · Cited by 44
Porta, M. G. D., & Malcovati, L. (2009) · Haematologica · doi:10.3324/haematol.2009.005702 · Cited by 44
Gökçe, M., Bilginer, Y., Beşbaş, N., Özaltın, F., Cetin, M., Gümrük, F., & Özen, S. (2012) · Lupus · doi:10.1177/0961203312443721 · Cited by 45
Löfström, B., Backlin, C., Sundström, C., Hellström‐Lindberg, E., Ekbom, A., & Lundberg, I. E. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep204 · Cited by 42
Eastmond, D. A., Keshava, N., & Sonawane, B. R. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.04.001 · Cited by 43
Therapy-related myeloid neoplasms following treatment with radioiodine
Schroeder, T. A., Kuendgen, A., Käyser, S., Kröger, N. M., Braulke, F., Platzbecker, U., Klärner, V., Zohren, F., Haase, D. T., Stadler, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049114 · Cited by 38
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
Joannides, M., Mays, A. N., Mistry, A. R., Hasan, S. K., Reiter, A., Wiemels, J. L., Felix, C. A., Lo‐Coco, F., Osheroff, N., Solomon, E., et al. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.045 · Cited by 35
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
Valentini, C. G., Fianchi, L., Voso, M. T., Caira, M., Leone, G. G. M., & Pagano, L. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.069 · Cited by 34
Self-citationLutzmann, M., Bernex, F., de Jesus, C. D. C., Hodroj, D., Marty, C., Plo, I., Vainchenker, W., Tosolini, M., Forichon, L., Bret, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.095 · Cited by 33
Second malignancies after breast cancer: The impact of adjuvant therapy
Dong, C., & Chen, L. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.250 · Cited by 33
Secondary acute myeloid leukemia – a single center experience
Szotkowski, T., Rohoň, P., Zapletalova, L., Sičová, K., Hubácek, J., & Indrák, K. (2010) · Neoplasma · doi:10.4149/neo_2010_02_170 · Cited by 32
Ojha, R. P., Fischbach, L. A., Zhou, Y., Felini, M., Singh, K. P., & Thertulien, R. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.04.003 · Cited by 30
Secondary Acute Myeloid Leukemia
Winer, E. S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.003 · Cited by 29
Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα
Gibson, E. G., King, M. M., Mercer, S. L., & Deweese, J. E. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00209 · Cited by 29
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia
Ossenkoppele, G. J., & Montesinos, P. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.003 · Cited by 28
Gangatharan, S. A., Grove, C. S., P’ng, S., O'Reilly, J., Joske, D. J. L., Leahy, M. F., Threlfall, T. J., & Wright, M. P. (2013) · Internal Medicine Journal · doi:10.1111/imj.12169 · Cited by 28
Chemotherapy-induced genotoxic damage to bone marrow cells: long-term implications
May, J. E., Donaldson, C., Gynn, L. E., & Morse, H. (2018) · Mutagenesis · doi:10.1093/mutage/gey014 · Cited by 27
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes
Fabiani, E., D’Alò, F., Scardocci, A., Greco, M., Ruscio, A. D., Criscuolo, M., Fianchi, L., Pagano, L., Hohaus, S., Leone, G. G. M., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.10.012 · Cited by 26
Self-citationItzhar-Baïkian, N., Dessen, P., Toujani, S., Auger, N., Preudhomme, C., Richon, C., Lazar, V., Saada, V., Griscelli, A. B., Bourhis, J. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016623 · Cited by 26
Park, T. S., Choi, J. R., Yoon, S. H., Song, J., Kim, J., Kim, S. J., Kwon, O., & Min, Y. H. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.06.015 · Cited by 25
Myelodysplastic Syndromes (MDS)
Pleyer, L., Neureiter, D., Faber, V., & Greil, R. (2010) · Springer eBooks · doi:10.1007/978-3-211-79892-8_6 · Cited by 24
Radiotherapy- and Chemotherapy-Induced Myelodysplasia Syndrome
Sun, L.-M., Lin, C., Lin, M., Liang, J., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000000737 · Cited by 24
Cytotoxic effects of catechol to neuroblastoma N2a cells.
Lima, R. M. F., Alvarez, L. D. G., Costa, M. F. D., Costa, S. L., Clarêncio, J., & El-Bachá, R. D. S. (2008) · PubMed · Cited by 24
members, O. B. O. T. E. W. E. A. I. O., Pelkonen, O., Terron, A., Hernández, A. F., Menéndez, P. R., & Bennekou, S. H. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1986-x · Cited by 24
Franklin, J. G., Eichenauer, D. A., Becker, I., Monsef, I., & Engert, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008814.pub2 · Cited by 24
The molecular basis of familial chronic lymphocytic leukemia
Crowther-Swanepoel, D., & Houlston, R. S. (2009) · Haematologica · doi:10.3324/haematol.2009.006296 · Cited by 22
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
Rodríguez‐Sevilla, J. J., Ademà, V., Garcia‐Manero, G., & Colla, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100940 · Cited by 23
Kim, M., & Williams, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018764923 · Cited by 21
Calip, G. S., Moran, K. M., Sweiss, K. I., Patel, P. R., Wu, Z., Adimadhyam, S., Lee, T. A., Ko, N. Y., Quigley, J. G., & Chiu, B. C. ‐. (2018) · Cancer · doi:10.1002/cncr.31914 · Cited by 21
Cole, M. E., & STRAIR, R. K. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181bedb74 · Cited by 21
Duong, V. H., Lancet, J. E., Alrawi, E., Al‐Ali, N., Perkins, J. B., Field, T. L., Epling‐Burnette, P. K., Zhang, L., List, A. F., & Komrokji, R. S. (2013) · Leukemia Research · doi:10.1016/j.leukres.2012.12.012 · Cited by 20
Jeyaratnam, D. C., Baduin, B. S., Hansen, M. H., Hansen, M., Jørgensen, J. M., Aggerholm, A., Ommen, H. B., Hokland, P., & Nyvold, C. G. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.02.005 · Cited by 19
Wang, S. A., Abruzzo, L. V., Hasserjian, R. P., Zhang, L., Hu, Y., Zhang, Y., Zhao, M., Galili, N., Raza, A., Medeiros, L. J., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.07.018 · Cited by 18
Scholz, M. R., Engert, A., Franklin, J. G., Josting, A., Diehl, V., Hasenclever, D., & Loeffler, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq408 · Cited by 17
Diamond, H. R., Ornellas, M. H., Órfão, A., Gomes, B. E., Campos, M. M., Fernandez, T. D. S., da Silva, R. I., Alves, G., Lage, C. A. S., Da, S., et al. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-39 · Cited by 17
Kamat, N., Khidhir, M. A., Jaloudi, M., Hussain, S., Alashari, M., Qawasmeh, K. H. A. A., & Rannug, U. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-373 · Cited by 17
Sasaki, K., Jabbour, E. J., Cortes, J. E., Kadia, T. M., Garcia‐Manero, G., Borthakur, G. M., Jain, P., Pierce, S. A., Daver, N. G., Takahashi, K., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.015 · Cited by 17
Long-Term Outcomes of Myeloid Growth Factor Treatment
Lyman, G. H., & Dale, D. C. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0077 · Cited by 16
Kamat, N., Khidhir, M. A., Hussain, S., Alashari, M., & Rannug, U. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0118-4 · Cited by 15
Olme, C.-H., Finnon, R., Brown, N., Kabacik, S., Bouffler, S. D., & Badie, C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.05.019 · Cited by 16
Inoue, A., Kawakami, C., Takitani, K., & Tamai, H. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000042 · Cited by 15
Secondary Acute Myeloid Leukemia in Survivors of Hodgkin Lymphoma
Bhatt, V. R., Giri, S., Verma, V., Dahal, S., Shah, B. K., Pathak, R., Bociek, R. G., Vose, J. M., & Armitage, J. O. (2016) · Future Oncology · doi:10.2217/fon-2016-0048 · Cited by 15
Pullarkat, V. A., Slovak, M. L., Dagis, A., Bedell, V., Somlo, G., Nakamura, R., Stein, A. S., O’Donnell, M., Nademanee, A., Teotico, A. L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp232 · Cited by 14
Behzad, M. M., Abbasi, M., Oliaei, I., Ghorbani, S., & Rafieemehr, H. (2021) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2021.58 · Cited by 14
Racke, F. K., Cole, C., Walker, A., Jones, J. A., & Heerema, N. A. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.11.001 · Cited by 13
Therapy‐related leukemia following chemoradiotherapy for esophageal cancer
Mimura, N., Tsujimura, H., Ise, M., Sakai, C., Takagi, T., Nagata, M., & Kumagai, K. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01487.x · Cited by 13
Cafaro, A., Giannini, M. B., Silimbani, P., Cangini, D., Masini, C., di Rorà, A. G. L., Simonetti, G., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07017-2 · Cited by 13
Slovak, M. L., Bedell, V., Lew, D. L., Albain, K. S., Ellis, G. K., Livingston, R. B., Martino, S., Perez, E. A., Hortobágyi, G. N., Sher, D., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0597-5 · Cited by 14
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
Stoddart, A., McNerney, M. E., Bartom, E. T., Bergerson, R. J., Young, D. J., Qian, Z., Wang, J., Fernald, A. A., Davis, E. M., Larson, R. A., et al. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.019 · Cited by 13
Cordone, I., Amodeo, R., Bellesi, S., Bottan, F., Buccisano, F., Propris, M. S. D., Masi, S., Panichi, V., Scerpa, M. C., Annibali, O., et al. (2023) · Cancers · doi:10.3390/cancers15072060 · Cited by 11
Weich, N., Núñez, M., Galimberti, G., Elena, G. D. C. R. P., Acevedo, S., Larripa, I. B., & Fundia, A. F. (2015) · Hematology · doi:10.1179/1607845415y.0000000007 · Cited by 11
Aptamers for DNA Damage and Repair
McKeague, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102212 · Cited by 11
Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report
Zhang, Y.-C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4402 · Cited by 11
Gonzalez, M. M., Kidd, L. R., Quesada, J. R., Nguyen, N., & Chen, L. (2013) · PubMed · Cited by 11
Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
Boquoi, A., Banahan, S. M., Mohring, A., Savickaite, I., Strapatsas, J., Hildebrandt, B., Kobbe, G., Gattermann, N., Haas, R. R., Schroeder, T. A., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04775-1 · Cited by 10
Wang, Z., Yin, Y., Wang, J., Zhu, Y., Li, X., & Zeng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716741 · Cited by 10
Altered chromatin modifications in AML1/RUNX1 breakpoint regions involved in (8;21) translocation
Stuardo, M., Martínez, M., Hidalgo, K., Montecino, M. A., Javed, A., Lian, J. B., Stein, G. S., Stein, J. L., & Gutierrez, S. E. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21599 · Cited by 10
Zimmerman, Z. F., Scott, B. L., Gopal, A. K., Sandmaier, B. M., Maloney, D. G., & Deeg, H. J. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.180 · Cited by 10
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
Papanikolaou, X. D., Barlogie, B., & Usmani, S. Z. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.047 · Cited by 9
Shim, H., Chi, H., Jang, S., Seo, E., Park, C., Lee, J., Lee, J., & Lee, K. (2010) · The Korean Journal of Hematology · doi:10.5045/kjh.2010.45.3.177 · Cited by 9
Myelodysplastic Syndrome and Acute Myeloid Leukemia Risk Associated With Solid Tumor Chemotherapy
Patel, S. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5617 · Cited by 9
Metadata
- Authors
- Leone, G., Pagano, L., Ben-Yehuda, D., & Voso, M. T.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Leone, G.
- Venue
- Haematologica
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 1389-1398
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2148305047
- Cited by
- 236
- References
- 73
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 4 · 2023: 9 · 2022: 16 · 2021: 15 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 15 · 2012: 19
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukemia, secondary malignancies, alkylating agents, topoisomerase II inhibitors, azathioprine, DNA mismatch repair, 11q23 translocation, Hodgkin's disease, non-Hodgkin lymphoma, total body irradiation, autologous stem cell transplantation, granulocyte colony-stimulating factor, acute lymphoblastic leukemia, breast cancer, germ cell tumors, genetic susceptibility, polymorphism
- MeSH terms
- Animals, Disease Susceptibility, DNA, DNA Topoisomerases, Type II, DNA Repair, Humans, Leukemia, Myelodysplastic Syndromes, Polymorphism, Genetic, Radiotherapy, Risk Factors, Incidence, Topoisomerase II Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
